MIRM Stock Forecast & Price Target

Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. With a pipeline of treatments for diseases such as Alagille syndrome, PFIC, and ALGS, and a recently acquired late-stage candidate for fibrodysplasia ossificans progressiva, the company has a diverse portfolio of potential therapies. The acquisition of zilurgisertib, with positive late-breaking presentation data at ENDO, showcases the company's strategic approach to licensing, which could drive significant long-term value. Additionally, the recent positive VISTAS results and planned NDA filing in 2026 for volixibat, a potential treatment for PSC, further supports the company's efforts towards expanding its rare-liver commercial infrastructure. Overall, Mirum Pharmaceuticals appears to be on a strong growth trajectory and is well-positioned to capture a significant share of the rare and orphan disease market.

Mirum Pharmaceuticals is a biopharmaceutical company, primarily driven by its lead product Livmarli (maralixibat) which is approved to treat cholestatic pruritus in patients with Alagille syndrome and is also being developed for other rare diseases. The company faces significant commercial risk from competitive pressure, clinical risk from the need for further studies in pipeline indications, regulatory risk from uncharted regulatory waters, and financial risk as it continues to incur net losses and may need to raise additional capital. Upcoming clinical data readouts in 2026-2027 and the potential advantage of brelovitug over competitors may offer a positive outlook, but achieving a target price of $150 faces risks such as commercial success, clinical outcomes, dilution, legal challenges, and competition.